CN101700354A - Traditional Chinese medicine for treating diabetes - Google Patents
Traditional Chinese medicine for treating diabetes Download PDFInfo
- Publication number
- CN101700354A CN101700354A CN200910117610A CN200910117610A CN101700354A CN 101700354 A CN101700354 A CN 101700354A CN 200910117610 A CN200910117610 A CN 200910117610A CN 200910117610 A CN200910117610 A CN 200910117610A CN 101700354 A CN101700354 A CN 101700354A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- radix
- traditional chinese
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 36
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 22
- 241000255791 Bombyx Species 0.000 claims description 11
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 9
- 210000003038 endothelium Anatomy 0.000 claims description 9
- 239000008517 radix Trichosanthis Substances 0.000 claims description 9
- 239000009636 Huang Qi Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 30
- 210000004369 blood Anatomy 0.000 abstract description 23
- 239000008280 blood Substances 0.000 abstract description 23
- 239000008103 glucose Substances 0.000 abstract description 22
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 18
- 208000024891 symptom Diseases 0.000 abstract description 17
- 230000000291 postprandial effect Effects 0.000 abstract description 16
- 102000004877 Insulin Human genes 0.000 abstract description 9
- 108090001061 Insulin Proteins 0.000 abstract description 9
- 229940125396 insulin Drugs 0.000 abstract description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 abstract description 8
- 210000004185 liver Anatomy 0.000 abstract description 8
- 231100000331 toxic Toxicity 0.000 abstract description 7
- 230000002588 toxic effect Effects 0.000 abstract description 7
- 210000004923 pancreatic tissue Anatomy 0.000 abstract description 5
- 230000008439 repair process Effects 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 230000006870 function Effects 0.000 abstract description 4
- 210000002216 heart Anatomy 0.000 abstract description 4
- 201000001421 hyperglycemia Diseases 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 3
- 230000003914 insulin secretion Effects 0.000 abstract description 3
- 230000000451 tissue damage Effects 0.000 abstract description 3
- 231100000827 tissue damage Toxicity 0.000 abstract description 3
- 241001465754 Metazoa Species 0.000 abstract description 2
- 210000003734 kidney Anatomy 0.000 abstract description 2
- 239000003390 Chinese drug Substances 0.000 abstract 1
- 235000002722 Dioscorea batatas Nutrition 0.000 abstract 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 abstract 1
- 240000001811 Dioscorea oppositifolia Species 0.000 abstract 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 abstract 1
- 244000302512 Momordica charantia Species 0.000 abstract 1
- 235000009811 Momordica charantia Nutrition 0.000 abstract 1
- 235000009812 Momordica cochinchinensis Nutrition 0.000 abstract 1
- 235000018365 Momordica dioica Nutrition 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 abstract 1
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 235000008434 ginseng Nutrition 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 33
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 21
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 12
- 235000012054 meals Nutrition 0.000 description 10
- 230000003907 kidney function Effects 0.000 description 9
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 8
- 241000605447 Anemarrhena Species 0.000 description 7
- 235000005903 Dioscorea Nutrition 0.000 description 6
- 241000234273 Dioscorea Species 0.000 description 6
- 235000000504 Dioscorea villosa Nutrition 0.000 description 6
- 241000212941 Glehnia Species 0.000 description 6
- 241000545442 Radix Species 0.000 description 6
- 241001530126 Scrophularia Species 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 235000004879 dioscorea Nutrition 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 102000007562 Serum Albumin Human genes 0.000 description 4
- 108010071390 Serum Albumin Proteins 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 4
- 229960001381 glipizide Drugs 0.000 description 4
- 239000004576 sand Substances 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 230000003908 liver function Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 230000002547 anomalous effect Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002562 urinalysis Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- HHMSPIAOYISBOU-IYQBICMXSA-N insulin rabbit Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 HHMSPIAOYISBOU-IYQBICMXSA-N 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 229940127017 oral antidiabetic Drugs 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine, in particular to a traditional Chinese medicine for treating diabetes, which is prepared from 20 traditional Chinese drugs comprising America ginseng, rhizoma anemarrhenae, balsam pear, Chinese yam and the like. The invention is developed on the principle of treating both principal and secondary aspect of disease in Chinese medicine; after diabetes is treated, the efficiency of treatment on the fasting blood-glucose is 30.6-50%, and the efficiency of the treatment on the postprandial blood sugar is 36-61.3%; and especially in the animal experiment, the traditional Chinese medicine can enable the sugar tolerance curve of the hyperglycaemia rabbit in a rabbit tetraoxypyrimidine-model to obviously descend, obviously enhance the sugar tolerance of rabbits and promote rabbits in the hyperglycemia state to excrete insulin, and has certain repair function on pancreatic tissue damage caused by tetraoxypyrimidine. The traditional Chinese medicine can enhance the insulin release for patients with diabetes after treatment, obviously increase the postprandial insulin and obviously improve the symptoms of diabetes. The clinical experiment indicates that the traditional Chinese medicine is safe to take and reliable in curative effect, have no abnormal effect on the functions of the heart, liver and kidney as well as the blood system, and have no other adverse effects and toxic or side effect.
Description
Technical field
The present invention relates to a kind of Chinese medicine, particularly a kind of Chinese medicine for the treatment of diabetes.
Background technology
Diabetes are one of the world's three big difficult and complicated illness, and in decades, countries in the world have been carried out long-term and unremitting research and development one after another.Twice important breakthrough arranged on treatment diabetes history: be the 1950's for the first time, China is synthetic insulin first, makes a stir all over the world; Be the appearance of biguanides and sulphanylureas oral antidiabetic drug for the second time, make the blood glucose of diabetics be able to temporary transient control.Be used for the used Chinese medicine and western medicine of clinical treatment at present and reached tens of kinds, but because diabetes pathology, etiological study are not also had substantial breakthrough so far, the treatment diabetes still are in the conceptual phase that blood sugar control, glucose in urine increase the stage and prevent comprehensive complication.In addition, the patient takes Western medicine for a long time, can bring side effect to internal organs such as kidney, liver, the heart, spleen, stomaches.Domestic its drug effect of various pure Chinese medicinal preparations of coming out newly developed also all is in blood sugar control, glucose in urine increases the stage, without any a kind of medicine there is repair in human pancreas tissue injury and obtains convictive scientific basis.
Summary of the invention
The purpose of this invention is to provide a kind of pure Chinese medicine, can effectively treat diabetes, nurse one's health metabolism disorder comprehensively, damage has certain repair to pancreatic tissue, to recover islet function, impels insulin to discharge, the balance blood sugar level, the pure Chinese medicinal preparation of prevention and treatment diabetes.
For achieving the above object, the technical scheme that is adopted is: a kind of Chinese medicine for the treatment of diabetes, its prescription is: Radix Panacis Quinquefolii 1-5 part, Rhizoma Anemarrhenae 2-6 part, Gypsum Fibrosum 1-5 part, Fructus Momordicae charantiae 3-8 part, Bombyx bombycis 2-6 part, Radix Astragali 1-5 part, Rhizoma Dioscoreae 1-5 part, Radix Rehmanniae 1-5 part, Radix Scrophulariae 1-5 part, Radix Glehniae 1-5 part, Radix Ophiopogonis 1-5 part, Rhizoma Polygonati Odorati 1-5 part, Rhizoma Polygonati 1-5 part, Radix Trichosanthis 1-5 part, Endothelium Corneum Gigeriae Galli 1-5 part, Rhizoma Coptidis 1-5 part, Fructus Corni 1-5 part, Fructus Lycii 2-7 part, Fructus Ligustri Lucidi 2-7 part, Herba Epimedii 1-5 part.
Above-mentioned Bombyx bombycis is dupion.
Above-mentioned Fructus Lycii is that produce in Ningxia.
The present invention is based on the principle of traditional Chinese medical science treating both the principal and secondary aspects of a disease, diabetes are being adopted on the basis of traditional blood sugar lowering therapy, by a large amount of clinical trials, in the treatment diabetes, particularly the type ii diabetes aspect has supplementing QI and nourishing YIN, replenishing body fluid and clearing away heat pathogen, the effect of blood sugar lowering, after taking, not only blood glucose, glucose in urine are effectively controlled; The recovery of function such as energy, muscle power is also very satisfied, and the saccharifying serum albumin has obvious decline, and the pancreatic tissue damage that alloxan is caused has certain repair.
Not finding in a large amount of clinical trials and animal experiment has anomalous effects and other untoward reaction and toxic and side effects to the heart, liver, renal function, blood system.
The specific embodiment
According to the prescription that the technical program provided, adopt existing Chinese medicine preparation method to make capsule or tablet, electuary, carry out following clinical trial, the prescription of embodiment sees Table one.
The type ii diabetes diagnostic criteria: with reference to the diabetes etiology typing standard of publishing on the Diabetes Care magazine in July, 1997, all diagnosis of diabetes standards that meets, the insulin release test result meets one of following condition person and promptly is diagnosed as type 2 diabetes mellitus.1. with the insulin resistant the relative insufficient insulin of main companion.2. insulin obviously lacks companion's insulin resistant.3. not making a definite diagnosis the person 1. can not do, 2..
Chinese medical discrimination diagnostic criteria: deficiency of both QI and YIN or double heat syndrome: (1) primary symptom: fatigue and weakness, thirst and liking drink, easy hungry polyphagia, frequent micturition.(2) inferior disease: dysphoria with feverish sensation in the chest palms and soles, spontaneous perspiration or night sweat, breathe hard lazy speech, cardiopalmus, constipation.(3) tongue arteries and veins: red tongue with a little fluid or corpulent tongue are big, thready pulse or count accurately.Indispensable 1 of above primary symptom adds 2 of time diseases, and is promptly diagnosable with reference to the tongue arteries and veins.
Embodiment 1
In Xiyuan Hospital, Chinese Medicine Academy of China's clinical trial, observe patient's 50 examples of type ii diabetes altogether, adopt prescription as the embodiment in the table one 1, its clinical test results is as follows:
Experimenter group: meet the heat syndrome diagnosis of holding concurrently of type 2 diabetes mellitus diagnosis and traditional Chinese medical science deficiency of both QI and YIN.
Therapeutic scheme:
Test group: the present invention,, every day 3 times, obey, around the course of treatment before the meal half an hour by each 6.
Matched group: JIANGTANGNING JIAONANG, each 6, every day 3 times, obey half an hour before the meal, around the course of treatment.
Duration of test forbids merging other blood sugar lowering Western medicine of application, and it is as follows to merge the unified regulation of Western medicine:
Moderate state of an illness experimenter: enlightening sand (glipizide) 2.5mg 3 times/day obeys before the meal half an hour.
Severe state of an illness experimenter: enlightening sand (glipizide) 5mg 2 times/day (sooner or later respectively once) obeys before the meal half an hour.
Main curative effect index: symptom, sign, fasting glucose, post-prandial glycemia, glycolated hemoglobin, saccharifying serum albumin.
Secondary efficacy index: blood fat, hemorheology.
Safety indexes: routine blood test, routine urinalysis, just routine, electrocardiogram, liver function, renal function
Statistics: the efficacy analysis employing meets the scheme collection to be analyzed, and safety analysis adopts the intentional analysis collection to analyze.
Case 50 examples are observed in this test altogether.
Test group curative effect: fasting glucose curative effect obvious effective rate 36.00%, post-prandial glycemia obvious effective rate 36.00%, tcm symptom obvious effective rate 32.00%;
Matched group curative effect: fasting glucose curative effect obvious effective rate 28.00%, post-prandial glycemia obvious effective rate 32.00%, tcm symptom obvious effective rate 32.00%;
Do not see toxic and side effects and untoward reaction in the process of the test to hepatic and renal function and blood system.
Embodiment 2
In No.1 Hospital of Guiyang Traditional Chinese Medicine College, observe patient's 84 examples of type ii diabetes altogether, adopt prescription as the embodiment in the table one 2, its clinical test results is as follows:
Test group medicine: Chinese medicine of the present invention, each 6, every day 3 times, the course of treatment: 6 weeks
Matched group medicine: JIANGTANGNING JIAONANG, each 6, every day 3 times, the course of treatment: 6 weeks
This clinical trial is observed altogether and is met scheme case 84 examples, and according to above statistical analysis, main result is as follows.
Test group 63 examples: fasting glucose curative effect obvious effective rate 41.3%, post-prandial glycemia obvious effective rate 52.4%, tcm symptom obvious effective rate 57.2%;
Matched group 21 examples: fasting glucose curative effect obvious effective rate 23.8%, post-prandial glycemia obvious effective rate 33.3%, tcm symptom obvious effective rate 61.9%.
Group 84 examples are gone in this test altogether, and test group is included 63 examples altogether in, do not find untoward reaction in the test and to electrocardiogram, liver, renal function, blood system toxic side effect.
Embodiment 3
In Xiyuan Hospital, Chinese Medicine Academy of China's clinical trial, observe patient's 200 examples of type ii diabetes altogether, adopt prescription as the embodiment in the table one 3, its clinical test results is as follows:
Experimenter group: meet the heat syndrome diagnosis of holding concurrently of type 2 diabetes mellitus diagnosis and traditional Chinese medical science deficiency of both QI and YIN.
Therapeutic scheme:
Test group: Chinese medicine of the present invention, each 6, every day 3 times, obey half an hour before the meal, around the course of treatment.
Matched group: JIANGTANGNING JIAONANG, each 6, every day 3 times, obey half an hour before the meal, around the course of treatment.
Duration of test forbids merging other blood sugar lowering Western medicine of application, and it is as follows to merge the unified regulation of Western medicine:
Moderate state of an illness experimenter: enlightening sand (glipizide) 2.5mg 3 times/day obeys before the meal half an hour.
Severe state of an illness experimenter: enlightening sand (glipizide) 5mg 2 times/day (sooner or later respectively once) obeys before the meal half an hour.
Main curative effect index: symptom, sign, fasting glucose, post-prandial glycemia, glycolated hemoglobin, saccharifying serum albumin.
Secondary efficacy index: blood fat, hemorheology.
Safety indexes: routine blood test, routine urinalysis, just routine, electrocardiogram, liver function, renal function
Statistics: the efficacy analysis employing meets the scheme collection to be analyzed, and safety analysis adopts the intentional analysis collection to analyze.
Test group 100 examples: fasting glucose curative effect obvious effective rate 41%, post-prandial glycemia obvious effective rate 43%, tcm symptom obvious effective rate 39%;
Matched group 100 examples: fasting glucose curative effect obvious effective rate 32%, post-prandial glycemia obvious effective rate 30%, tcm symptom obvious effective rate 31%;
Test group is better than matched group to the curative effect of 2 hours blood glucose after the meal, and significant difference is arranged.Tired slow-witted weak doing well,improving is better than matched group.To improving significantly before and after cholesterol, the low density lipoprotein, LDL treatment.
After the test group treatment after the meal islets of langerhans have obvious rising, significant difference is arranged.The treatment of control group front and back are to the change there was no significant difference of insulin.
The improvement of glycolated hemoglobin has significant difference before and after the test group treatment, and glycolated hemoglobin improves no difference of science of statistics before and after the treatment of control group
Safety results: test group is gone into group 109 examples, and not observing has anomalous effects and other untoward reaction to the heart, liver, renal function, blood system.
Conclusion: treatment by Chinese herbs type 2 diabetes mellitus of the present invention (deficiency of both QI and YIN hold concurrently heat syndrome) is safe and effective.
Test group treatment back saccharifying serum albumin has obvious decline, and significant difference is arranged.
Embodiment 4
In Hospital Attached to Shandong Chinese Medical Univ., patient's case 80 examples of type ii diabetes are observed in clinical trial altogether, adopt the prescription as the embodiment in the table one 4, administration such as embodiment 1.According to statistical analysis, main result is as follows.
Test group 60 examples: fasting glucose curative effect obvious effective rate 50.0%, post-prandial glycemia obvious effective rate 53.3%, tcm symptom obvious effective rate 25.0%;
Matched group 20 examples: fasting glucose curative effect obvious effective rate 30.0%, post-prandial glycemia obvious effective rate 35.0%, tcm symptom obvious effective rate 25.0%;
Group 80 examples are gone in this test altogether, do not find untoward reaction in the test and to electrocardiogram, liver, renal function, blood system toxic side effect.
Embodiment 5
No.1 Hospital Attached to Hunan College of Traditional Chinese Medicine, clinical trial are observed patient's case 77 examples of type ii diabetes altogether, adopt the prescription as the embodiment in the table one 5, administration such as embodiment 2.According to statistical analysis, main result is as follows.
Test group 59 examples: fasting glucose curative effect obvious effective rate 49.2%, post-prandial glycemia obvious effective rate 55.9%, tcm symptom obvious effective rate 23.7%;
Matched group 18 examples: fasting glucose curative effect obvious effective rate 33.3%, post-prandial glycemia obvious effective rate 38.9%, tcm symptom obvious effective rate 27.8%;
Group 77 examples are gone in this test altogether, do not find untoward reaction in the test and to electrocardiogram, liver, renal function, blood system toxic side effect.
Embodiment 6
The hospital of traditional Chinese hospital, Xi'an, patient's case 84 examples of type ii diabetes are observed in clinical trial altogether, adopt the prescription as the embodiment in the table one 6, administration such as embodiment 1.Its clinical test results is as follows:
Test group 62 examples: fasting glucose curative effect obvious effective rate 30.6%, post-prandial glycemia obvious effective rate 61.3%, tcm symptom obvious effective rate 32.3%;
Matched group 22 examples: fasting glucose curative effect obvious effective rate 13.6%, post-prandial glycemia obvious effective rate 31.8%, tcm symptom obvious effective rate 18.2%;
Group 84 examples are gone in this test altogether, find with trial drug clearly relevant untoward reaction is arranged in the test and to electrocardiogram, liver, renal function, blood system toxic side effect.
Embodiment 7
In the pharmacodynamic study of Xian Medical Univ's clinical pharmacology institute, adopt and test as the prescription of the embodiment in the table one 7 and the prescription of embodiment 1-6, the result is as follows:
Adopt required standard, gastric infusion has obvious reduction effect to normal mouse blood sugar level; Alloxan model hyperglycemic rat, rabbit blood sugar level, mice epinephrine hyperglycemia there is obvious reduction effect; Rabbit alloxan model hyperglycemia rabbit glucose tolerance curve is obviously moved down, can obviously improve the rabbit carbohydrate tolerance; Also can promote rabbit insulin secretion under the high sugared state; The pancreatic tissue damage that alloxan is caused has certain repair.
Up to now, this is that other similar Chinese patent medicine is unexistent, and this conclusion has been checked and approved by State Food and Drug Administration and write the medicine operation instructions.
Table one: embodiment and prescription correspondence table
| Embodiment | Prescription |
| 1 | 1 part of Radix Panacis Quinquefolii, 2 parts of the Rhizoma Anemarrhenaes, 1 part in Gypsum Fibrosum, 3 parts in Fructus Momordicae charantiae, 2 parts of Bombyx bombycis, 1 part of the Radix Astragali, 1 part of Rhizoma Dioscoreae, 1 part in the Radix Rehmanniae, 1 part of Radix Scrophulariae, 1 part of Radix Glehniae, 1 part of Radix Ophiopogonis, 1 part of Rhizoma Polygonati Odorati, 1 part of Rhizoma Polygonati, 1 part of Radix Trichosanthis, 1 part of Endothelium Corneum Gigeriae Galli, 1 part of Rhizoma Coptidis, 1 part of Fructus Corni, 2 parts of Fructus Lycii, 2 parts of Fructus Ligustri Lucidi, 1 part of Herba Epimedii. |
| Embodiment | Prescription |
| ??2 | 4 parts of Radix Panacis Quinquefoliis, 5 parts of the Rhizoma Anemarrhenaes, 5 parts in Gypsum Fibrosum, 8 parts in Fructus Momordicae charantiae, 6 parts of Bombyx bombycis, 5 parts of the Radixs Astragali, 5 parts of Rhizoma Dioscoreaes, 5 parts in the Radix Rehmanniae, 5 parts of Radix Scrophulariaes, 5 parts of Radix Glehniaes, 5 parts of Radix Ophiopogonis, 5 parts of Rhizoma Polygonati Odorati, 5 parts of Rhizoma Polygonatis, 5 parts of Radix Trichosanthis, 5 parts of Endothelium Corneum Gigeriae Galli, 5 parts of Rhizoma Coptidis, 5 parts of Fructus Corni, 5 parts of Fructus Lycii, 6 parts of Fructus Ligustri Lucidi, 5 parts of Herba Epimedii |
| ??3 | 3 parts of Radix Panacis Quinquefoliis, 4 parts of the Rhizoma Anemarrhenaes, 3 parts in Gypsum Fibrosum, 5 parts in Fructus Momordicae charantiae, 4 parts of Bombyx bombycis, 3 parts of the Radixs Astragali, 3 parts of Rhizoma Dioscoreaes, 3 parts in the Radix Rehmanniae, 3 parts of Radix Scrophulariaes, 3 parts of Radix Glehniaes, 3 parts of Radix Ophiopogonis, 3 parts of Rhizoma Polygonati Odorati, 3 parts of Rhizoma Polygonatis, 3 parts of Radix Trichosanthis, 3 parts of Endothelium Corneum Gigeriae Galli, 3 parts of Rhizoma Coptidis, 3 parts of Fructus Corni, 4 parts of Fructus Lycii, 4 parts of Fructus Ligustri Lucidi, 3 parts of Herba Epimedii |
| ??4 | 2 parts of Radix Panacis Quinquefoliis, 3 parts of the Rhizoma Anemarrhenaes, 4 parts in Gypsum Fibrosum, 7 parts in Fructus Momordicae charantiae, 5 parts of Bombyx bombycis, 4 parts of the Radixs Astragali, 4 parts of Rhizoma Dioscoreaes, 4 parts in the Radix Rehmanniae, 4 parts of Radix Scrophulariaes, 4 parts of Radix Glehniaes, 4 parts of Radix Ophiopogonis, 4 parts of Rhizoma Polygonati Odorati, 4 parts of Rhizoma Polygonatis, 4 parts of Radix Trichosanthis, 4 parts of Endothelium Corneum Gigeriae Galli, 4 parts of Rhizoma Coptidis, 4 parts of Fructus Corni, 6 parts of Fructus Lycii, 6 parts of Fructus Ligustri Lucidi, 4 parts of Herba Epimedii |
| ??5 | 4 parts of Radix Panacis Quinquefoliis, 5 parts of the Rhizoma Anemarrhenaes, 2 parts in Gypsum Fibrosum, 4 parts in Fructus Momordicae charantiae, 3 parts of Bombyx bombycis, 2 parts of the Radixs Astragali, 2 parts of Rhizoma Dioscoreaes, 2 parts in the Radix Rehmanniae, 2 parts of Radix Scrophulariaes, 2 parts of Radix Glehniaes, 2 parts of Radix Ophiopogonis, 2 parts of Rhizoma Polygonati Odorati, 2 parts of Rhizoma Polygonatis, 2 parts of Radix Trichosanthis, 2 parts of Endothelium Corneum Gigeriae Galli, 2 parts of Rhizoma Coptidis, 2 parts of Fructus Corni, 5 parts of Fructus Lycii, 3 parts of Fructus Ligustri Lucidi, 2 parts of Herba Epimedii |
| ??6 | 4 parts of Radix Panacis Quinquefoliis, 5 parts of the Rhizoma Anemarrhenaes, 2 parts in Gypsum Fibrosum, 4 parts in Fructus Momordicae charantiae, 3 parts of Bombyx bombycis, 2 parts of the Radixs Astragali, 2 parts of Rhizoma Dioscoreaes, 2 parts in the Radix Rehmanniae, 2 parts of Radix Scrophulariaes, 2 parts of Radix Glehniaes, 2 parts of Radix Ophiopogonis, 2 parts of Rhizoma Polygonati Odorati, 2 parts of Rhizoma Polygonatis, 2 parts of Radix Trichosanthis, 2 parts of Endothelium Corneum Gigeriae Galli, 2 parts of Rhizoma Coptidis, 2 parts of Fructus Corni, 3 parts of Fructus Lycii, 5 parts of Fructus Ligustri Lucidi, 2 parts of Herba Epimedii |
| ??7 | 5 parts of Radix Panacis Quinquefoliis, 6 parts of the Rhizoma Anemarrhenaes, 5 parts in Gypsum Fibrosum, 8 parts in Fructus Momordicae charantiae, 6 parts of Bombyx bombycis, 5 parts of the Radixs Astragali, 5 parts of Rhizoma Dioscoreaes, 5 parts in the Radix Rehmanniae, 5 parts of Radix Scrophulariaes, 5 parts of Radix Glehniaes, 5 parts of Radix Ophiopogonis, 5 parts of Rhizoma Polygonati Odorati, 5 parts of Rhizoma Polygonatis, 5 parts of Radix Trichosanthis, 5 parts of Endothelium Corneum Gigeriae Galli, 5 parts of Rhizoma Coptidis, 5 parts of Fructus Corni, 7 parts of Fructus Lycii, 7 parts of Fructus Ligustri Lucidi, 5 parts of Herba Epimedii |
Claims (3)
1. Chinese medicine for the treatment of diabetes, its prescription is: Radix Panacis Quinquefolii 1-5 part, Rhizoma Anemarrhenae 2-6 part, Gypsum Fibrosum 1-5 part, Fructus Momordicae charantiae 3-8 part, Bombyx bombycis 2-6 part, Radix Astragali 1-5 part, Rhizoma Dioscoreae 1-5 part, Radix Rehmanniae 1-5 part, Radix Scrophulariae 1-5 part, Radix Glehniae 1-5 part, Radix Ophiopogonis 1-5 part, Rhizoma Polygonati Odorati 1-5 part, Rhizoma Polygonati 1-5 part, Radix Trichosanthis 1-5 part, Endothelium Corneum Gigeriae Galli 1-5 part, Rhizoma Coptidis 1-5 part, Fructus Corni 1-5 part, Fructus Lycii 2-7 part, Fructus Ligustri Lucidi 2-7 part, Herba Epimedii 1-5 part.
2. the Chinese medicine of treatment diabetes according to claim 1 is characterized in that above-mentioned Bombyx bombycis is dupion.
3. the Chinese medicine of treatment diabetes according to claim 2 is characterized in that above-mentioned Fructus Lycii is that produce in Ningxia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009101176109A CN101700354B (en) | 2009-11-20 | 2009-11-20 | Traditional Chinese medicine for treating diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009101176109A CN101700354B (en) | 2009-11-20 | 2009-11-20 | Traditional Chinese medicine for treating diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101700354A true CN101700354A (en) | 2010-05-05 |
| CN101700354B CN101700354B (en) | 2011-05-04 |
Family
ID=42155298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009101176109A Active CN101700354B (en) | 2009-11-20 | 2009-11-20 | Traditional Chinese medicine for treating diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101700354B (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102671010A (en) * | 2011-12-23 | 2012-09-19 | 山东省千佛山医院 | Medicament for treating diabetes and preparation method thereof |
| CN102772630A (en) * | 2012-08-11 | 2012-11-14 | 段尚勤 | Medicine for treating type-II diabetes mellitus |
| CN102846960A (en) * | 2012-07-25 | 2013-01-02 | 李承平 | Capsules for nourishing yin and promoting body fluid |
| CN103446503A (en) * | 2013-07-26 | 2013-12-18 | 杨德俊 | Traditional Chinese medicine composition for treating type II diabetes mellitus |
| CN103520527A (en) * | 2013-09-27 | 2014-01-22 | 沙学 | Health-care medicine with blood glucose decrease effect and preparation method thereof |
| CN103989937A (en) * | 2014-05-28 | 2014-08-20 | 赵红侠 | Medicament for treating diabetic ketoacidosis and preparation method thereof |
| CN106668442A (en) * | 2015-11-10 | 2017-05-17 | 钟建国 | Traditional Chinese medicine for treating diabetes |
| CN108403951A (en) * | 2018-05-24 | 2018-08-17 | 大连根特生物工程技术有限公司 | A method of utilizing cordyceps fermenting and producing hypoglycemic health-care product |
| CN109806334A (en) * | 2019-04-12 | 2019-05-28 | 谢宁 | Join stilbene kidney tonifying diabetes pill |
| CN112316054A (en) * | 2020-11-19 | 2021-02-05 | 冉明 | Pharmaceutical composition for repairing islet tissue in vivo |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1057448C (en) * | 1994-02-01 | 2000-10-18 | 张树成 | Method for prepn. of medicinal introducing bag for treating diabetes mellitus |
| CN100475252C (en) * | 2006-06-29 | 2009-04-08 | 江界 | Chinese medicine for treating diabetes and preparation method thereof |
-
2009
- 2009-11-20 CN CN2009101176109A patent/CN101700354B/en active Active
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102671010A (en) * | 2011-12-23 | 2012-09-19 | 山东省千佛山医院 | Medicament for treating diabetes and preparation method thereof |
| CN102846960A (en) * | 2012-07-25 | 2013-01-02 | 李承平 | Capsules for nourishing yin and promoting body fluid |
| CN102772630A (en) * | 2012-08-11 | 2012-11-14 | 段尚勤 | Medicine for treating type-II diabetes mellitus |
| CN102772630B (en) * | 2012-08-11 | 2014-08-06 | 段尚勤 | Medicine for treating type-II diabetes mellitus |
| CN103446503A (en) * | 2013-07-26 | 2013-12-18 | 杨德俊 | Traditional Chinese medicine composition for treating type II diabetes mellitus |
| CN103520527A (en) * | 2013-09-27 | 2014-01-22 | 沙学 | Health-care medicine with blood glucose decrease effect and preparation method thereof |
| CN103989937A (en) * | 2014-05-28 | 2014-08-20 | 赵红侠 | Medicament for treating diabetic ketoacidosis and preparation method thereof |
| CN106668442A (en) * | 2015-11-10 | 2017-05-17 | 钟建国 | Traditional Chinese medicine for treating diabetes |
| CN108403951A (en) * | 2018-05-24 | 2018-08-17 | 大连根特生物工程技术有限公司 | A method of utilizing cordyceps fermenting and producing hypoglycemic health-care product |
| CN109806334A (en) * | 2019-04-12 | 2019-05-28 | 谢宁 | Join stilbene kidney tonifying diabetes pill |
| CN112316054A (en) * | 2020-11-19 | 2021-02-05 | 冉明 | Pharmaceutical composition for repairing islet tissue in vivo |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101700354B (en) | 2011-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101700354B (en) | Traditional Chinese medicine for treating diabetes | |
| CN101708295B (en) | Chinese medicinal preparation for treating diabetes and preparation methods thereof | |
| CN103566350B (en) | A kind of pharmaceutical composition with hypoglycemic effect | |
| CN101642529B (en) | Preparation capable of treating diabetes | |
| CN104645132A (en) | Traditional Chinese medicine composition for treating diabetic nephropathy, preparation method, traditional Chinese medicine preparation and application of traditional Chinese medicine composition | |
| CN103417846B (en) | Chinese medicine composition of a kind of blood sugar lowering and preparation method thereof | |
| CN102462834A (en) | Medicinal composition for controlling blood sugar of diabetic | |
| CN102631526B (en) | Chinese medicinal composition for treating diabetes mellitus | |
| CN104645066A (en) | Traditional Chinese medicine capable of nourishing yin, tonifying vital energy and reducing blood glucose | |
| CN102488830B (en) | Pharmaceutical composition for lowering blood sugar | |
| CN102872334B (en) | Application of medicinal composition for treating diabetes mellitus | |
| CN102114195B (en) | Anti-drug capsule prepared from pure traditional Chinese medicines | |
| CN102716276B (en) | Medicine for oral use for treating diabetes | |
| CN104208420A (en) | Traditional Chinese medicine for treating diabetes mellitus | |
| CN105434802A (en) | Pharmaceutical composition for treating diabetes, and preparation method and application thereof | |
| CN103211996B (en) | Preparation method of traditional Chinese medicine for treating diabetes mellitus | |
| CN102488846A (en) | Medicinal composition for treating diabetes mellitus | |
| CN101607031A (en) | Medicated wine of a kind of treatment and prevent diabetes and preparation method thereof and using method | |
| CN103230552B (en) | Traditional Chinese medicine for treating diabetes mellitus | |
| CN102485259A (en) | Preparation method and application of ginseng fruit medicinal dispersing tablets and buccal tablets | |
| CN102813808B (en) | Traditional Chinese medicine for treating yin and yang deficiency type diabetes | |
| CN103520684B (en) | Traditional Chinese medicine compound for reducing blood sugar | |
| CN101537102A (en) | Medical and edible dual-purpose composition for treating sugar diabetes and preparation method thereof | |
| CN102430040A (en) | Medicament for treating diabetes | |
| CN108743885A (en) | A kind of Chinese medicine and preparation method thereof for treating Diabetic Macrovascular Complications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PP01 | Preservation of patent right |
Effective date of registration: 20190826 Granted publication date: 20110504 |
|
| PP01 | Preservation of patent right | ||
| PD01 | Discharge of preservation of patent |
Date of cancellation: 20240301 Granted publication date: 20110504 |
|
| PD01 | Discharge of preservation of patent | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240306 Address after: Building G33, East Side of Tai Road and North Side of Xinyang Road, China Pharmaceutical City, Taizhou City, Jiangsu Province, 225316 Patentee after: Jiangsu Zhongyong Hongrui Pharmaceutical Co.,Ltd. Country or region after: China Address before: Room 410, Building 1, Development Zone, Jinfeng District, Yinchuan City, Ningxia Hui Autonomous Region, 750002 Patentee before: Ningxia Qianzongbao Research Institute of Diabetic & Nephropathy Country or region before: China |
|
| TR01 | Transfer of patent right |